These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 291945

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.
    Uyttenhove C, Van Snick J, Boon T.
    J Exp Med; 1980 Nov 01; 152(5):1175-83. PubMed ID: 6776226
    [Abstract] [Full Text] [Related]

  • 3. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line.
    Boon T, Van Pel A.
    Proc Natl Acad Sci U S A; 1978 Mar 01; 75(3):1519-23. PubMed ID: 274738
    [Abstract] [Full Text] [Related]

  • 4. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line.
    Boon T, Kellermann O.
    Proc Natl Acad Sci U S A; 1977 Jan 01; 74(1):272-5. PubMed ID: 264681
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation.
    Peppoloni S, Herberman RB, Gorelik E.
    Cancer Res; 1985 Jun 01; 45(6):2560-6. PubMed ID: 2580624
    [Abstract] [Full Text] [Related]

  • 8. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis.
    Van Pel A, Vessière F, Boon T.
    J Exp Med; 1983 Jun 01; 157(6):1992-2001. PubMed ID: 6602203
    [Abstract] [Full Text] [Related]

  • 9. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.
    Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M.
    J Exp Med; 1980 Nov 01; 152(5):1184-93. PubMed ID: 6776227
    [Abstract] [Full Text] [Related]

  • 10. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.
    Maryanski JL, Marchand M, Uyttenhove C, Boon T.
    Int J Cancer; 1983 Jan 15; 31(1):119-23. PubMed ID: 6187698
    [Abstract] [Full Text] [Related]

  • 11. Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815.
    Marchand M, Caspar P, Boon T.
    Eur J Cancer Clin Oncol; 1983 Nov 15; 19(11):1529-37. PubMed ID: 6196202
    [Abstract] [Full Text] [Related]

  • 12. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis.
    Van Pel A, Boon T.
    Proc Natl Acad Sci U S A; 1982 Aug 15; 79(15):4718-22. PubMed ID: 6981814
    [Abstract] [Full Text] [Related]

  • 13. Antigenic variants isolated from a mutagen-treated guinea pig fibrosarcoma.
    Zbar B, Sukumar S, Tanio Y, Terata N, Hovis J.
    Cancer Res; 1984 Nov 15; 44(11):5079-85. PubMed ID: 6488168
    [Abstract] [Full Text] [Related]

  • 14. Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts.
    Siesjö P, Visse E, Lindvall M, Salford L, Sjögren HO.
    Cancer Immunol Immunother; 1993 Jul 15; 37(1):67-74. PubMed ID: 8513454
    [Abstract] [Full Text] [Related]

  • 15. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids.
    Maryanski JL, Szpirer J, Szpirer C, Boon T.
    Somatic Cell Genet; 1983 May 15; 9(3):345-57. PubMed ID: 6407125
    [Abstract] [Full Text] [Related]

  • 16. Increase in H-2 antigen expression and immunogenicity of BL6 melanoma cells treated with N-methyl-N'-nitronitrosoguanidine.
    Gorelik E, Peppoloni S, Overton R, Herberman RB.
    Cancer Res; 1985 Nov 15; 45(11 Pt 1):5341-7. PubMed ID: 2413992
    [Abstract] [Full Text] [Related]

  • 17. Selection of strongly immunogenic "tum-" variants from tumors at high frequency using 5-azacytidine.
    Frost P, Liteplo RG, Donaghue TP, Kerbel RS.
    J Exp Med; 1984 May 01; 159(5):1491-501. PubMed ID: 6201588
    [Abstract] [Full Text] [Related]

  • 18. In situ augmentation of class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma.
    Elliott BE, Carlow DA, Ivimey L, Arnold M, Hampton N, Bosman P.
    Cancer Res; 1987 Sep 15; 47(18):4915-23. PubMed ID: 2441856
    [Abstract] [Full Text] [Related]

  • 19. Immunological characteristics of immunogenic variants induced in the MCA-F murine fibrosarcoma using 1-methyl-3-nitro-1-nitrosoguanidine, 5-aza-2'-deoxycytidine, or ultraviolet radiation.
    Simcik W, Frost P, LeGrue SJ.
    Cancer Res; 1989 Aug 01; 49(15):4192-8. PubMed ID: 2472875
    [Abstract] [Full Text] [Related]

  • 20. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens.
    Fuji H, Iribe H.
    Cancer Res; 1986 Nov 01; 46(11):5541-7. PubMed ID: 3489524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.